Literature DB >> 4014693

Enzyme-linked coagulation assay: a clot-based, solid-phase assay for thrombin.

G J Doellgast, H Rothberger.   

Abstract

A new, solid-phase microtiter plate assay for thrombin has been developed, using fibrinogen bound to wells of a microtiter plate and peroxidase-fibrinogen in solution as an indicator system. When small amounts of thrombin are added to the mixture, peroxidase-fibrin and plate-bound fibrin are formed, and the peroxidase-fibrin binds to the plate-bound fibrin. The amount of peroxidase-fibrin binding is proportional to the thrombin concentration and time of incubation. Using this assay, thrombin was measured at concentrations as low as 0.25 ng/ml (0.006 nM) in 150 microliter of sample. In the presence of the specific inhibitors benzamidine and D-phenylalanyl-L-prolyl-L-arginine chloromethyl ketone, the thrombin activity is reduced, at relative concentrations of inhibitors consistent with their affinities and mechanisms of action. The enzyme-linked coagulation assay is generally useful as a highly sensitive and convenient alternative to conventional "clot-based" tests of coagulation.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4014693     DOI: 10.1016/0003-2697(85)90310-0

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  2 in total

1.  Sensitive enzyme-linked immunosorbent assay for detection of Clostridium botulinum neurotoxins A, B, and E using signal amplification via enzyme-linked coagulation assay.

Authors:  G J Doellgast; M X Triscott; G A Beard; J D Bottoms; T Cheng; B H Roh; M G Roman; P A Hall; J E Brown
Journal:  J Clin Microbiol       Date:  1993-09       Impact factor: 5.948

2.  A gamma methionine-310 to threonine substitution and consequent N-glycosylation at gamma asparagine-308 identified in a congenital dysfibrinogenemia associated with posttraumatic bleeding, fibrinogen Asahi.

Authors:  K Yamazumi; K Shimura; S Terukina; N Takahashi; M Matsuda
Journal:  J Clin Invest       Date:  1989-05       Impact factor: 14.808

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.